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In addition, the authors deﬁned objective tumor response as
complete response (CR) and partial response (PR) in this article,
quite different from the deﬁnition in their previous article, which
excluded the complete response (CR)with the reason that patients
with complete response (CR) following the ﬁrst TACE did not
receive a further TACE session. We wonder whether the patients
with complete response (CR) after TACE-2 or TACE-3 received
further TACE sessions in their institutions. We suppose that the
distinct deﬁnitions of objective tumor response may diminish
the credibility of their study. All the above demonstrates that
the ART score is not as validated as we previously supposed.
All in all, further study is needed to fully validate the clinical
practice of ART-score regardless of its remarkable signiﬁcance in
helping distinguish patients who will beneﬁt from repeated
TACE.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Muller C, et al. The ART-
strategy: sequential assessment of the ART score predicts outcome of
patients with hepatocellular carcinoma re-treated with TACE. J Hepatol
2014;60:118–126.
[2] Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, et al. The ART
of decision making: retreatment with transarterial chemoembolization in
patients with hepatocellular carcinoma. Hepatology 2013;57:2261–2273.
[3] Lewandowski RJ, Mulcahy MF, Kulik LM, et al. Chemoembolization for
hepatocellular carcinoma: comprehensive imaging and survival analysis in a
172-patient cohort. Radiology 2010;255:955–965.
[4] Georgiades C, Geschwind JF, Harrison N, et al. Lack of response after initial
chemoembolization for hepatocellular carcinoma: does it predict failure of
subsequent treatment? Radiology 2012;265:115–123.
[5] Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial
chemoembolization for the treatment of hepatocellular carcinoma: consen-
sus recommendations and review by an international expert panel. Liver Int
2014;34:174–183.
[6] Song MJ, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, et al. Comparative
study between doxorubicin-eluting beads and conventional transarterial
chemoembolization for treatment of hepatocellular carcinoma. J Hepatol
2012;57:1244–1250.
[7] Varela M, Real MI, Burrel M. Chemoembolization of hepatocellular carci-
noma with drug eluting beads: efﬁcacy and doxorubicin pharmacokinetics. J
Hepatol 2007;46:474–481.
[8] Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Kim HS. Drug eluting beads
vs. conventional TACE for unresectable hepatocellular carcinoma: survival
beneﬁts and safety. J Clin Oncol 2009;27:4524.
[9] Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma.
Gastroenterology 2004;127:S179–S188.
[10] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet
2012;379:1245–1255.
Jian Wu
Wei Bai
Guohong Han⇑
Department of Liver Disease and Digestive Interventional Radiology,
Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military
Medical University, Xi’an, China⇑Corresponding author.
E-mail address: guohhan@126.com
Daiming Fan
State Key Laboratory of Cancer Biology and Xijing Hospital of
Digestive Diseases, Xijing Hospital,
Fourth Military Medical University, Xi’an, China
Fig. 2. Angiography of tumor before and after TACE. (A) DSA angiography
shows tumor staining in the right lobe of the liver in the ﬁrst TACE performance.
(B) The tumor staining disappears after chemoembolization. (C) DSA examination
shows tumor staining in the third TACE session. (D) The tumor staining
disappears after the third TACE procedure.
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JOURNAL OF HEPATOLOGYReply to the Letters to the Editor regarding the sequential ART-ScoreTo the Editor:
We would like to thank Yousuf and colleagues for the thoughtful
comments on our work regarding the sequential use of the ART
score to select patients for retreatment with TACE [1]. They are
right in commenting that the Child-Pugh score (CPS) consists of
5 variables but the reason why we use the change in CPS was thatJournal of Hepatology 20
Open access under CC BY-NC-ND license.in our uni- and multivariate analysis from the original ART-score
manuscript, the change in composite CPS was a better predictor
for survival than the change in the individual variables included
in the CPS [2]. In addition, from a practical point of view, the
CPS has to be calculated to evaluate the patient’s suitability with
regards to liver function for the selection for any treatment14 vol. 61 j 169–182 177
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Letters to the Editor
according to the BCLC staging classiﬁcation, so this information is
always available anyways. We also agree that the greatest weight
in the ART-score is put on the aspartate aminotransferase (AST)
and not on radiologic response. But this was derived from the
hazard ratio in the multivariate analysis giving the greatest
weight to the rising AST as opposed to other statistically signiﬁ-
cant parameters.
We acknowledge that the authors developed the HAP score
[3], but the HAP score serves a different purpose: it is a prog-
nostic score, which helps to subclassify BCLC-stage B patients
undergoing chemoembolization into different prognostic groups
prior the ﬁrst TACE treatment. In contrast, the ART-score, aims
to detect (1) patients that can tolerate repeated-TACE well and
(2) patients, whose liver function and prognosis would be
harmed by another occlusion of the arterial blood supply to
parts of the liver. So patients might be in a good prognostic
group by the HAP score or by the BCLC stage B subclassiﬁca-
tion at baseline, but a subgroup of these patients may present
with an ART of P2.5 points prior to TACE-2 with subsequent
dismal prognosis in case of retreatment with TACE. On the
other hand, some suboptimal candidates for TACE at baseline
may tolerate repeated TACE quite well as outlined by an ART
score of 0–1.5 points and therefore have a fairly good outcome
with TACE treatment, as detailed in our original ART-score
manuscript.
Regarding the comments by Han and colleagues we would
like to conﬁrm that even if a patient receives 2.5 points in the
ART-score through lack of radiologic response and an increase
in CPS by 1 point after TACE 1, he still is a poor candidate for
further TACE’s. It might be true that he might show a radiologic
response after the second TACE but this will lead to further
deterioration in his liver function and therefore a dismal prognosis
despite radiologic response. This has been clearly shown in our
initial art score manuscript. Therefore the recommendations
by different authors that patients should undergo at least two
TACE-procedures initially – statements made well before the
publication of the art score – cannot be supported anymore.
Regarding the impact of different TACE or TAE techniques, the
authorsmisunderstood themessagewe are giving: itmight be true
that treatment with DC-beads gives a better treatment respond
than cTACE (even though not supported by the published litera-
ture so far [4]), but thiswill be taken into account by the ART-score
anyway through the parameter ‘‘radiologic response’’. Thus, differ-
ent TACE techniques could have an impact on the ART-sore values;
but nevertheless, the ART-score values obtained retain their prog-
nostic signiﬁcance regardless of the technique used.Triple or dual therapy for
Optimizing sele
To the Editor:
We read with interest the paper by Andriulli et al. [1] about the
identiﬁcation of naïve HCV-1 patients who can be treated with
dual therapy according to baseline and on-treatment parameters.
178 Journal of Hepatology 201We disagree with the authors that the response deﬁnition is
different because we did not evaluate patients with complete
response in our initial ART-score manuscript: the deﬁnition was
the same but the inclusion criteria did not allow inclusion of
patients with less than 2 TACE-procedures (which was obviously
necessary to evaluate the impact of repeated TACE’s on outcome,
since patients with complete response do not receive retreatment
with TACE within three months if TACE is applied in a ‘‘on
demand’’ fashion). Patients that had a complete response after
TACE 2 or TACE 3 did not receive further TACE sessions in our
institutions, as outlined very clearly in the methods of our manu-
scripts. So the validation of the ART-score seems to be very robust
but we certainly welcome further evaluation of the ART-score in
different patient populations worldwide, in particular when
performed prospectively.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.HCV-1 naive patients?
ction tools
Important predictive factors of sustained virological response
(SVR) are the IL28B single-nucleotide polymorphisms (SNPs),
however the authors considered only the rs12979860 SNP, for-
getting the more important rs8099917 [2–4]; this is, in our opin-
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